, pub-5475981771945671, DIRECT, f08c47fec0942fa0

LianBio Announces Pricing of Initial Public Offering

LianBio Announces Pricing of Initial Public Offering

LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the pricing of its initial public offering of 20,312,500 American depositary shares at a public offering price of $16.00 per ADS, for gross proceeds of approximately $325.0 million, before deducting underwriting discounts and commissions and offering expenses.

Each ADS represents one ordinary share of LianBio, and all of the ADSs are being offered by LianBio. In addition, LianBio has granted the underwriters a 30-day option to purchase up to 3,046,875 additional ADSs at the initial public offering price, less underwriting discounts and commissions.

The ADSs are scheduled to begin trading on the Nasdaq Global Market on November 1, 2021 under the ticker symbol “LIAN,” and the offering is expected to close on November 3, 2021, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Jefferies LLC and BofA Securities, Inc. are acting as joint bookrunning managers for the offering. Raymond James is acting as lead manager for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on October 29, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at, and BofA Securities, Inc., Attn: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, North Carolina, 28255-0001, or by email at

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets.